Loading companies…
Loading companies…
United States · Biotech · Enterprise software
Develops programmable epigenetic medicines to treat genetic diseases like FSHD
| Announced | Round | Amount | Investors |
|---|---|---|---|
| Series C | $90M | abrdn — Role not disclosedAngelini Ventures — Role not disclosedCormorant Asset Management — Role not disclosedDuquesne Family Office — Role not disclosedFidelity Management & Research Company — Role not disclosedJanus Henderson Investors — Role not disclosedOctagon Capital — Role not disclosedReadout Capital — Role not disclosedSanofi Ventures — Role not disclosed |